Abbreviations:ALT (alanine aminotransferase), AST (aspartate aminotransferase), CI (confidence interval), ET (endothelin), ETRA (endothelin-receptor antagonist), IPAH (idiopathic pulmonary arterial hypertension), PAH (pulmonary arterial hypertension), PAH-CHD (pulmonary arterial hypertension associated with congenital heart defect), PAH-CTD (pulmonary arterial hypertension associated with connective tissue disease), 6MWD (6-min walk distance), STRIDE (Sitaxsentan To Relieve Impaired Exercise), ULN (upper limit of normal range), WHO (World Health Organization)
Purchase one-time access:Academic and Personal
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Pulmonary arterial hypertension.N Engl J Med. 2004; 351: 1655-1665
- Treatment of pulmonary arterial hypertension.N Engl J Med. 2004; 351: 1425-1436
- Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.Chest. 2004; 126: 78S-92S
- Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.Eur Heart J. 2006; 27: 589-595
- Endothelin receptor antagonists.Pharmacol Ther. 2006; 110: 386-414
- Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension.J Cardiovasc Pharmacol. 2004; 44: 187-191
- Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.J Am Coll Cardiol. 2006; 47: 2049-2056
- Tracleer (bosentan) prescribing information, updated August 2004.Accessed March 5, 2007)
- Results of European post-marketing surveillance of bosentan in pulmonary hypertension.Eur Respir J. 2007; 30: 338-344
- Sitaxsentan therapy for pulmonary arterial hypertension.Am J Respir Crit Care Med. 2004; 169: 441-447
- Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.J Heart Lung Transplant. 2007; 26: 63-69
- Survival with first-line bosentan in patients with primary pulmonary hypertension.Eur Respir J. 2005; 25: 244-249
- Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.Thorax. 2005; 60: 1025-1030
- Bosentan therapy for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.Ann Rheum Dis. 2006; 65: 1336-1340
- Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.J Heart Lung Transplant. 2005; 24: 1626-1631
- Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.Heart. 2006; 92: 926-932
- Endothelin receptor antagonists in pulmonary arterial hypertension.J Am Coll Cardiol. 2004; 43: 62S-67S
- Clinical challenges in pulmonary hypertension: Roger S. Mitchell lecture.Chest. 2005; 128: 622S-628S
- Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.Eur Respir J. 2005; 26: 858-863
- Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.Am J Respir Crit Care Med. 2006; 174: 1257-1263
Simmoneau G, Burgess G, Collings L, et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension. Proceedings of the American Thoracic Society 2006 International Conference. San Diego, CA, May 19–24, 2006; A58
The authors have no conflicts of interest to disclose.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).